UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
17.76 x 2 25.30 x 7
Pre-market by (Cboe BZX)
24.84 +0.70 (+2.90%) 03/24/25 [NASDAQ]
17.76 x 2 25.30 x 7
Pre-market 24.44 -0.40 (-1.61%) 05:01 ET
Quote Overview for Mon, Mar 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
24.11
Day High
25.08
Open 24.40
Previous Close 24.14 24.14
Volume 1,032,900 1,032,900
Avg Vol 970,125 970,125
Stochastic %K 87.33% 87.33%
Weighted Alpha +52.07 +52.07
5-Day Change +1.53 (+6.56%) +1.53 (+6.56%)
52-Week Range 11.16 - 31.67 11.16 - 31.67
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,149,496
  • Shares Outstanding, K 46,276
  • Annual Sales, $ 700,970 K
  • Annual Income, $ -99,560 K
  • EBIT $ 147 M
  • EBITDA $ 229 M
  • 60-Month Beta 0.86
  • Price/Sales 1.59
  • Price/Cash Flow 5.52
  • Price/Book 1.41

Options Overview Details

View History
  • Implied Volatility 54.18% ( -6.88%)
  • Historical Volatility 40.08%
  • IV Percentile 26%
  • IV Rank 14.09%
  • IV High 197.17% on 07/15/24
  • IV Low 30.72% on 06/17/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 52
  • Volume Avg (30-Day) 268
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 4,061
  • Open Int (30-Day) 4,727

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.42
  • Number of Estimates 5
  • High Estimate 0.56
  • Low Estimate 0.27
  • Prior Year 0.42
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.83 +13.81%
on 03/12/25
Period Open: 25.25
26.69 -6.93%
on 02/26/25
-0.41 (-1.62%)
since 02/24/25
3-Month
18.17 +36.71%
on 01/06/25
Period Open: 19.47
27.59 -9.97%
on 01/30/25
+5.37 (+27.58%)
since 12/24/24
52-Week
11.16 +122.50%
on 08/13/24
Period Open: 28.67
31.67 -21.57%
on 05/17/24
-3.83 (-13.36%)
since 03/22/24

Most Recent Stories

More News
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

PCRX : 24.84 (+2.90%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRX : 24.84 (+2.90%)
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,

The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.With investors feeling the jitters from tariff concerns and rising...

OPCH : 34.71 (+0.38%)
JAZZ : 142.02 (+2.35%)
PCRX : 24.84 (+2.90%)
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Esperion Therapeutics ESPR incurred a fourth-quarter 2024 loss of 10 cents per share (excluding one-time expenses of loss on extinguishment of debt and exchange transaction), which was narrower than the...

ESPR : 1.7400 (+2.96%)
RIGL : 20.54 (+1.68%)
PCRX : 24.84 (+2.90%)
Bull of the Day: Pacira BioSciences (PCRX)

Yes, the market has certainly seen its share of volatility recently. It’s led to some treacherous slides in equity prices. It seems that the high beta names are really getting slapped down. In most cases,...

PCRX : 24.84 (+2.90%)
Ensign Group Expands Healthcare Portfolio With Key Acquisitions

The Ensign Group, Inc. ENSG recently purchased the real estate and operations of a healthcare campus in Oregon, one skilled nursing facility and another senior living unit in Alaska, a skilled nursing...

JAZZ : 142.02 (+2.35%)
LMAT : 86.07 (+3.09%)
PCRX : 24.84 (+2.90%)
ENSG : 130.40 (+1.68%)
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

Puma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted...

FOLD : 8.69 (-3.50%)
IMCR : 29.64 (-0.57%)
PBYI : 3.47 (-1.14%)
PCRX : 24.84 (+2.90%)
Pacira: Q4 Earnings Snapshot

Pacira: Q4 Earnings Snapshot

PCRX : 24.84 (+2.90%)
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

PCRX : 24.84 (+2.90%)
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

PCRX : 24.84 (+2.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 26.21
2nd Resistance Point 25.64
1st Resistance Point 25.24
Last Price 24.84
1st Support Level 24.28
2nd Support Level 23.71
3rd Support Level 23.31

See More

52-Week High 31.67
Last Price 24.84
Fibonacci 61.8% 23.84
Fibonacci 50% 21.42
Fibonacci 38.2% 19.00
52-Week Low 11.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals